Treatment of post-allogeneic hematopoietic stem cell transplant cytopenias with sequential doses of multipotent mesenchymal stromal/stem cells.

Almudena Navarro-BailónMiriam López-ParraÁlvaro Veiga-VazEva María VillarónMaría Díez-CampeloAna África MartínEstefanía Pérez-LópezMónica CabreroLourdes VázquezLucía López-CorralFermín Sánchez-Guijo

Published in: Cytotherapy (2024)

In summary, the sequential infusion of third-party MSCs emerges as a viable and safe therapeutic option, exhibiting potential benefits for patients experiencing cytopenias following allo-SCT.

Keyphrases

hematopoietic stem cell
stem cells
bone marrow
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
stem cell transplantation
mesenchymal stem cells
peritoneal dialysis
low dose
prognostic factors
cell therapy
patient reported outcomes
high dose
combination therapy